Evidence map›Paper›PMID 38274857›Full record

ArticleAddiction neuroscience2023

Chronic oral methylphenidate plus fluoxetine treatment in adolescent rats increases cocaine self-administration.

Daniela Senior, Madison McCarthy, Rania Ahmed, Shannon Klein, Wen Xuan Lee, Michael Hadjiargyrou, David Komatsu, Heinz Steiner, Panayotis K Thanos

Open access · goldAbstract read
In one paragraph

Article in Addiction neuroscience, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.6field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Daniela SeniorBehavioral Neuropharmacology and Neuroimaging Laboratory (BNNL), Clinical Research Institute on Addictions, Department of Pharmacology and Toxicology, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo, NY 14051, USA.
Madison McCarthyBehavioral Neuropharmacology and Neuroimaging Laboratory (BNNL), Clinical Research Institute on Addictions, Department of Pharmacology and Toxicology, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo, NY 14051, USA.
Rania AhmedBehavioral Neuropharmacology and Neuroimaging Laboratory (BNNL), Clinical Research Institute on Addictions, Department of Pharmacology and Toxicology, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo, NY 14051, USA.
Shannon KleinBehavioral Neuropharmacology and Neuroimaging Laboratory (BNNL), Clinical Research Institute on Addictions, Department of Pharmacology and Toxicology, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo, NY 14051, USA.
Wen Xuan LeeBehavioral Neuropharmacology and Neuroimaging Laboratory (BNNL), Clinical Research Institute on Addictions, Department of Pharmacology and Toxicology, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo, NY 14051, USA.
Michael HadjiargyrouDepartment of Biological and Chemical Sciences, New York Institute of Technology, Old Westbury, NY, USA.
David KomatsuDepartment of Orthopedics, Stony Brook University, Stony Brook, NY, USA.
Heinz SteinerStanson Toshok Center for Brain Function and Repair, Rosalind Franklin University of Medicine and Science, North Chicago, IL 60064, USA.
Panayotis K ThanosBehavioral Neuropharmacology and Neuroimaging Laboratory (BNNL), Clinical Research Institute on Addictions, Department of Pharmacology and Toxicology, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo, NY 14051, USA.
University at Buffalo, State University of New York · USNew York Institute of Technology · USRosalind Franklin University of Medicine and Science · USStony Brook University · US

Funding

Serotonin receptors that potentiate addiction-related behavioral and molecular effects induced by methylphenidate plus SSRI exposureR01DA046794 · NIDA · ROSALIND FRANKLIN UNIV OF MEDICINE & SCI · PI BOLANOS, CARLOS A., STEINER, HEINZ · 2019 to 2023
$1.7M
Skeletal Effects of MethylphenidateR01HD070888 · NICHD · STATE UNIVERSITY NEW YORK STONY BROOK · PI KOMATSU, DAVID E · 2013 to 2017
$1.6M
NICHD NIH HHS R01 HD070888NIDA NIH HHS R01 DA046794
6 · The paper itself

Abstract

Background: Depression and attention deficit hyperactivity disorder are known to be comorbid. Treatment of these commonly coexisting diseases typically involves the combined prescription of methylphenidate (MP), a psychostimulant, and fluoxetine (FLX), a selective serotonin reuptake inhibitor (SSRI). MP and cocaine have similar mechanisms of action and this study examined the effects of chronic treatment of MP combined with FLX on cocaine consumption in rats. Methods: Four groups of rats received access to drinking solutions of water (control), MP (30/60 mg/kg/day), FLX (20 mg/kg/day), or the combination of MP (30/60 mg/kg/day) plus FLX (20 mg/kg/day), during 8 h per day for one month. Following these drug treatments, rats were allowed to self-administer cocaine for 14 days. Results: Our results showed that, during the first week of cocaine self-administration, the MP-treated rats had significantly greater numbers of active lever presses (plus 127%) and increased consumption of cocaine compared to the control rats. In contrast, during week two of cocaine self-administration, the rats treated with the MP + FLX combination showed significantly more lever presses (plus 198%) and significantly greater cocaine consumption (plus 84%) compared to the water controls. Conclusion: Chronic oral treatment during adolescence with the combination of MP plus FLX resulted in increased cocaine use after 2 weeks of cocaine self-administration in rats. These novel findings suggest that the combined exposure to these two drugs chronically, during adolescence, may produce increased vulnerability towards cocaine abuse during young adulthood.

Indexed as

AddictionBehaviorPsychostimulantsRewardSerotonin reuptake inhibitorsSubstance abuse

Identifiers

PMID38274857
PMCPMC10809890
OpenAlexW4386187597

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.